RemeGen Co

RemeGen Co Profit per Employee

The Profit per Employee of RemeGen Co (688331.SS) as of Oct 16, 2026 is 212,642.05 CNY. In the previous year, Profit per Employee was -440,684.51 CNY — a change of -148.25% (higher).

Profit per Employee

212,642.05CNY

YoY

-148.25%

Last updated:

Profit per Employee of RemeGen Co is 2025 212,642.05 CNY. Profit per Employee of RemeGen Co was 2024 -440,684.51 CNY. It decreases by -148.25% higher compared to the previous year.

The RemeGen Co Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2018
-81,016.81 CNY
Jan 1, 2019
-129,135.65 CNY
Jan 1, 2020
-209,430.07 CNY
Jan 1, 2021
82,910.56 CNY
Jan 1, 2022
-299,769.04 CNY
Jan 1, 2023
-453,550.15 CNY
Jan 1, 2024
-440,684.51 CNY
Jan 1, 2025
212,642.05 CNY
The RemeGen Co Profit per Employee history
YEARProfit per EmployeeYoY
212,642.05CNY-148.25%
-440,684.51CNY-2.84%
-453,550.15CNY+51.30%
-299,769.04CNY-461.56%
82,910.56CNY-139.59%
-209,430.07CNY+62.18%
-129,135.65CNY+59.39%
-81,016.81CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd, listed on the Shanghai Stock Exchange under ticker 688331.SS, is a biotechnology company headquartered in Yantai, China. The company went public on November 9, 2020, and currently employs 3,332 full-time staff. RemeGen focuses on the research, development, and manufacturing of innovative biopharmaceuticals, with a particular emphasis on therapeutic antibody drugs. Its product portfolio includes antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. The company's main products are tetacept (RC18), veldicitumab (RC48), and dual-target fusion protein (RC28), which are designed to treat conditions such as autoimmune diseases, oncology, and ophthalmology. RemeGen primarily operates within the domestic Chinese market, targeting major disease areas with its biopharmaceutical solutions. The company's website is www.remegen.cn, providing further information on its operations and products. RemeGen's business model centers on the discovery, development, and commercialization of advanced therapeutic antibodies, aiming to address significant unmet medical needs in the healthcare sector. With a strong focus on innovation, the company is positioned to contribute to the growing biotechnology landscape in China. Its operations reflect a commitment to developing cutting-edge treatments for complex health conditions, leveraging its expertise in antibody-based therapies. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

Profit per Employee of RemeGen Co is 212,642.05 CNY in 2025.

Profit per Employee of RemeGen Co changed from -440,684.51 CNY to 212,642.05 CNY, representing a -148.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's RemeGen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — RemeGen Co

All Key Metrics — RemeGen Co